Evommune Inc. picked up rights outside of greater China to an oral, preclinical VAV1-directed molecular glue degrader (MGD) ...

Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for ...

This summer’s U.S. FDA clearance of the oral pan-RAS inhibitor Rasonque (daraxonrasib) from Revolution Medicines Inc. provided hope for pancreatic ductal adenocarcinoma (PDAC) patients, and results ...

Despite a concerted effort to speed trial setup, the number of patients taking part in industry-sponsored clinical studies in ...

Five weeks after winning U.S. FDA approval of Emcitate (tiratricol) to treat peripheral thyrotoxicosis in those with MCT8 ...

SMN1 replacement using AAV9 has improved survival and motor outcomes in spinal muscular atrophy (SMA), but inefficient CNS delivery necessitates high systemic doses, potentially narrowing the ...

Shanghai Henlius Biotech Inc.’s HLX-109, an anti-IL1RAP monoclonal antibody, has received approval from the Human Research ...

For the third time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled its regularly scheduled meeting last month due to ongoing litigation. The cancellation made ...

T-Therapeutics Ltd. has raised $133 million in an oversubscribed series B, providing the means to deliver clinical proof of concept for its T-cell receptor-CD3 bispecifics in solid tumors and ...

Abbvie Inc. is paying Nxera Pharma Co. Ltd. $100 million up front for worldwide rights to NXE-0033744, a phase II-ready oral EP4 receptor agonist designed to act locally in the gastrointestinal tract ...

Alethio Therapeutics Ltd. has closed a £67 million (US$90.3 million) series A round that with a fair wind will see its lead ...

A pair of popular modalities stands at the back-end-loaded, potential $7 billion-plus deal inked by Boehringer Ingelheim GmbH ...